JP2009535045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009535045A5 JP2009535045A5 JP2009508205A JP2009508205A JP2009535045A5 JP 2009535045 A5 JP2009535045 A5 JP 2009535045A5 JP 2009508205 A JP2009508205 A JP 2009508205A JP 2009508205 A JP2009508205 A JP 2009508205A JP 2009535045 A5 JP2009535045 A5 JP 2009535045A5
- Authority
- JP
- Japan
- Prior art keywords
- sirna
- nucleotides
- alkyl
- modification
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004459 Small interfering RNA Proteins 0.000 claims description 110
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 210000004211 gastric acid Anatomy 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 description 73
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
- 238000011534 incubation Methods 0.000 description 8
- 238000004255 ion exchange chromatography Methods 0.000 description 8
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000012226 gene silencing method Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000874159 Mus musculus Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000013413 tumor xenograft mouse model Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0608838.9A GB0608838D0 (en) | 2006-05-04 | 2006-05-04 | Organic compounds |
| PCT/EP2007/003867 WO2007128477A2 (en) | 2006-05-04 | 2007-05-02 | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200081A Division JP2013005811A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2012200083A Division JP2013005812A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2013035574A Division JP2013128488A (ja) | 2006-05-04 | 2013-02-26 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535045A JP2009535045A (ja) | 2009-10-01 |
| JP2009535045A5 true JP2009535045A5 (enExample) | 2012-01-05 |
Family
ID=36603932
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508205A Pending JP2009535045A (ja) | 2006-05-04 | 2007-05-02 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2012200081A Pending JP2013005811A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2012200083A Pending JP2013005812A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2013035574A Pending JP2013128488A (ja) | 2006-05-04 | 2013-02-26 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200081A Pending JP2013005811A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2012200083A Pending JP2013005812A (ja) | 2006-05-04 | 2012-09-12 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
| JP2013035574A Pending JP2013128488A (ja) | 2006-05-04 | 2013-02-26 | 経口投与用の低分子干渉リボ核酸（ｓｉＲＮＡ） |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8084600B2 (enExample) |
| EP (7) | EP2759596B1 (enExample) |
| JP (4) | JP2009535045A (enExample) |
| KR (4) | KR101378199B1 (enExample) |
| CN (2) | CN101437944B (enExample) |
| AU (1) | AU2007247458B2 (enExample) |
| BR (1) | BRPI0711555A2 (enExample) |
| CA (4) | CA2846817A1 (enExample) |
| ES (2) | ES2595079T3 (enExample) |
| GB (1) | GB0608838D0 (enExample) |
| IN (3) | IN2014DN10872A (enExample) |
| MX (1) | MX2008014007A (enExample) |
| RU (2) | RU2008147665A (enExample) |
| WO (1) | WO2007128477A2 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| US8309530B2 (en) | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
| WO2010111891A1 (zh) * | 2009-04-03 | 2010-10-07 | 北京大学 | 修饰的寡聚核酸分子及其制备方法和应用 |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| KR101605932B1 (ko) | 2009-12-18 | 2016-03-24 | 노파르티스 아게 | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 |
| EP3721943A1 (en) | 2009-12-23 | 2020-10-14 | Novartis AG | Lipids, lipid compositions and methods of using them |
| WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
| JP2013519869A (ja) | 2010-02-10 | 2013-05-30 | ノバルティス アーゲー | 筋肉成長のための方法および化合物 |
| JP5857378B2 (ja) | 2010-04-23 | 2016-02-10 | アローヘッド リサーチ コーポレイション | ベータ−ＥＮａＣ−関連疾患を処置するための有機組成物 |
| ES2372237B1 (es) * | 2010-04-27 | 2013-01-24 | Consejo Superior De Investigaciones Científicas (Csic) | Oligonucleótidos modificados como reguladores de la expresión génica. |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| CA2818662C (en) | 2010-10-22 | 2021-07-06 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid molecule inducing rna interference, and uses thereof |
| EP2636678A4 (en) * | 2010-11-04 | 2013-11-20 | Consejo Superior Investigacion | DERIVATIVES OF SMALL INTERFERING RNAS AND USE THEREOF |
| CN102719434A (zh) * | 2011-03-31 | 2012-10-10 | 百奥迈科生物技术有限公司 | 抑制rna干扰脱靶效应的特异性修饰 |
| EP3248982A1 (en) | 2011-07-19 | 2017-11-29 | Wave Life Sciences Ltd. | Thiosulfonate reagents for the synthesis of functionalized nucleic acids |
| EP3098314B1 (en) | 2011-09-02 | 2019-03-13 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| EP2770054A4 (en) * | 2011-10-19 | 2015-09-02 | Riken | ACTIVATION OF FUNCTIONAL NUCLEIC ACIDS BY SPECIFIC MODIFICATION |
| US9534222B2 (en) * | 2011-11-15 | 2017-01-03 | University Of Utah Research Foundation | Morpholinos, morpholino upregulating, and associated methods |
| BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| US9506069B2 (en) | 2012-04-19 | 2016-11-29 | University Of Utah Research Foundation | Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization |
| CN109481455A (zh) | 2012-05-02 | 2019-03-19 | 箭头研究公司 | 治疗kras相关疾病的有机组合物 |
| EP3514236A1 (en) | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| AU2014205036A1 (en) | 2013-01-08 | 2015-07-30 | Benitec Biopharma Limited | Age-related macular degeneration treatment |
| US9868949B2 (en) | 2013-02-28 | 2018-01-16 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat EPAS1-related diseases |
| WO2014144799A2 (en) * | 2013-03-15 | 2014-09-18 | New York University | siRNA TARGETING HSR1 |
| WO2015051135A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compositions to treat hepcidin-related diseases |
| CN105683163B (zh) | 2013-10-04 | 2018-11-09 | 诺华股份有限公司 | RNA干扰中使用的RNAi剂的3’端帽 |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| WO2015051044A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| EP3052107B1 (en) | 2013-10-04 | 2018-05-02 | Novartis AG | Organic compounds to treat hepatitis b virus |
| EP2865758A1 (en) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene |
| EP2865756A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene. |
| EP2865757A1 (en) | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene. |
| US9936114B2 (en) * | 2013-10-25 | 2018-04-03 | Elwha Llc | Mobile device for requesting the capture of an image |
| US10900083B2 (en) | 2013-12-20 | 2021-01-26 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| MX2016009290A (es) | 2014-01-16 | 2017-02-28 | Wave Life Sciences Ltd | Diseño quiral. |
| JP2014141531A (ja) * | 2014-05-10 | 2014-08-07 | Isao Kajisa | 完成版がん根絶経口薬 |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| WO2016011123A1 (en) | 2014-07-16 | 2016-01-21 | Arrowhead Research Corporation | Organic compositions to treat apoc3-related diseases |
| CN107075570B (zh) * | 2014-08-07 | 2021-01-05 | 财团法人工业技术研究院 | 小干扰rna以及含其之用于抑制半乳糖凝集素-12表现及/或促进脂肪分解的医药组成物及其用途 |
| WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| WO2016089883A1 (en) | 2014-12-01 | 2016-06-09 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| US20180296537A1 (en) | 2015-06-05 | 2018-10-18 | Novartis Ag | Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders |
| JP7402479B2 (ja) | 2015-07-14 | 2023-12-21 | トランサルガエ イスラエル リミテッド | 干渉ｒｎａ分子を送達する飼料としてのトランスジェニック微細藻類およびその使用 |
| MA44908A (fr) | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
| EP3377630A4 (en) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| WO2017134526A1 (en) | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb |
| CN108779463B (zh) | 2016-02-02 | 2022-05-24 | 奥利克斯医药有限公司 | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 |
| WO2017178883A2 (en) | 2016-04-11 | 2017-10-19 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
| US11591600B2 (en) | 2017-02-10 | 2023-02-28 | OliX Pharmaceuticals. Inc. | Long double-stranded RNA for RNA interference |
| WO2019014656A1 (en) | 2017-07-14 | 2019-01-17 | Han Si Ping | METALLIC OLIGONUCLEOTIDE JONCTIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| EP3665281A4 (en) | 2017-08-10 | 2021-05-05 | City of Hope | CONDITIONAL SIRNA AND ITS USE IN THE TREATMENT OF CARDIAC HYERTROPHY |
| SG11201912178VA (en) | 2017-09-11 | 2020-01-30 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| US20210123016A1 (en) | 2018-05-02 | 2021-04-29 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
| JP2022518384A (ja) | 2019-01-09 | 2022-03-15 | アローヘッド ファーマシューティカルズ インコーポレイテッド | ＨＩＦ－２アルファ（ＥＰＡＳ１）の発現を阻害するためのＲＮＡｉ剤、その組成物及び使用方法 |
| TW202440941A (zh) | 2022-12-20 | 2024-10-16 | 瑞士商諾華公司 | 核酸連接方法 |
| AR131405A1 (es) | 2022-12-20 | 2025-03-19 | Novartis Ag | Ligasas modificadas y usos de las mismas |
| EP4560020A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| EP4560019A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| CN119040329B (zh) * | 2024-10-29 | 2025-03-18 | 南京大学 | 一种靶向胶质母细胞瘤的siRNA及其应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69009854D1 (de) | 1989-05-02 | 1994-07-21 | Schlumberger Technology Bv | Zündsystem für einen besonders geformten Sprengsatz eines Geschosslochers. |
| DE69033495T2 (de) * | 1989-10-24 | 2000-07-20 | Isis Pharmaceuticals, Inc. | 2'-modifizierte nukleotide |
| US5670633A (en) * | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US6399754B1 (en) * | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| NZ245720A (en) | 1992-01-22 | 1995-12-21 | Hoechst Ag | Oligonucleotide analogues; use as gene expression inhibitor or dna probe |
| US6033909A (en) * | 1992-01-22 | 2000-03-07 | Hoechst Aktiengesellschaft | Oligonucleotide analogs, their preparation and use |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| DE69634084T2 (de) * | 1995-06-07 | 2005-12-08 | Inex Pharmaceuticals Corp. | Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| AU6271598A (en) * | 1997-02-06 | 1998-08-26 | Epoch Pharmaceuticals, Inc. | Targeted modification of the ccr-5 gene |
| DE69841002D1 (de) * | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6211349B1 (en) * | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20050233329A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US20030190635A1 (en) * | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| EP1229134A3 (en) | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| ATE412892T1 (de) * | 2001-02-15 | 2008-11-15 | Unibio S R L | Enzymtest zur bestimmung von krankheitsrisiken in verbindung mit der anwesenheit von sialidase oder prolidase aktivität in körperflüssigkeit von frauen |
| CA2526831C (en) | 2001-05-18 | 2012-07-31 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US20070032441A1 (en) * | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
| US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| CA2448320A1 (en) | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| AU2009200231B2 (en) | 2001-07-23 | 2012-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| CA2454183C (en) | 2001-07-23 | 2016-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| US20090247606A1 (en) * | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| US8258288B2 (en) * | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| ES2389024T3 (es) | 2002-08-05 | 2012-10-22 | Silence Therapeutics Aktiengesellschaft | Moléculas de RNA interferentes de extremos romos |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| JP4605799B2 (ja) | 2003-04-02 | 2011-01-05 | ダーマコン， インコーポレイテッド | Ｒｎａ干渉において使用するための修飾ポリヌクレオチド |
| CA2521464C (en) * | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| WO2004092383A2 (en) | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| ES2702942T3 (es) * | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
| EP1636385A4 (en) * | 2003-06-24 | 2010-06-02 | Mirus Bio Corp | INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| US7201736B2 (en) * | 2003-08-28 | 2007-04-10 | Smiths Medical Asd, Inc. | Needle protection assembly |
| EP1765847A4 (en) * | 2004-05-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | NUCLEASERESISTENT DOUBLE-STRANDED RIBONUCLEIC ACID |
| GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2006
- 2006-05-04 GB GBGB0608838.9A patent/GB0608838D0/en not_active Ceased
-
2007
- 2007-05-02 EP EP14163854.4A patent/EP2759596B1/en active Active
- 2007-05-02 EP EP14163856.9A patent/EP2762568A1/en not_active Withdrawn
- 2007-05-02 ES ES14163854.4T patent/ES2595079T3/es active Active
- 2007-05-02 KR KR1020137019633A patent/KR101378199B1/ko active Active
- 2007-05-02 AU AU2007247458A patent/AU2007247458B2/en active Active
- 2007-05-02 EP EP10184136.9A patent/EP2322617B1/en not_active Not-in-force
- 2007-05-02 BR BRPI0711555-5A patent/BRPI0711555A2/pt not_active IP Right Cessation
- 2007-05-02 CN CN2007800161675A patent/CN101437944B/zh not_active Expired - Fee Related
- 2007-05-02 US US12/299,396 patent/US8084600B2/en active Active
- 2007-05-02 JP JP2009508205A patent/JP2009535045A/ja active Pending
- 2007-05-02 EP EP09169772A patent/EP2135950B1/en not_active Not-in-force
- 2007-05-02 CA CA2846817A patent/CA2846817A1/en not_active Abandoned
- 2007-05-02 RU RU2008147665/13A patent/RU2008147665A/ru not_active Application Discontinuation
- 2007-05-02 CA CA2649876A patent/CA2649876C/en active Active
- 2007-05-02 MX MX2008014007A patent/MX2008014007A/es active IP Right Grant
- 2007-05-02 EP EP07724793A patent/EP2013343A2/en not_active Withdrawn
- 2007-05-02 EP EP14163857.7A patent/EP2765196A1/en not_active Withdrawn
- 2007-05-02 KR KR1020087029546A patent/KR101345062B1/ko active Active
- 2007-05-02 KR KR1020137019631A patent/KR101384880B1/ko active Active
- 2007-05-02 CA CA2846732A patent/CA2846732C/en active Active
- 2007-05-02 ES ES09169772T patent/ES2398680T3/es active Active
- 2007-05-02 KR KR1020137019632A patent/KR101385923B1/ko active Active
- 2007-05-02 CN CN2013101469750A patent/CN103224934A/zh active Pending
- 2007-05-02 WO PCT/EP2007/003867 patent/WO2007128477A2/en not_active Ceased
- 2007-05-02 CA CA2846756A patent/CA2846756A1/en not_active Abandoned
- 2007-05-02 EP EP16174066.7A patent/EP3121278B1/en active Active
-
2010
- 2010-06-03 RU RU2010122640/10A patent/RU2010122640A/ru not_active Application Discontinuation
-
2011
- 2011-08-26 US US13/218,941 patent/US8344128B2/en active Active
- 2011-08-26 US US13/218,835 patent/US8404831B2/en active Active
- 2011-08-26 US US13/218,880 patent/US8404832B2/en active Active
-
2012
- 2012-09-12 JP JP2012200081A patent/JP2013005811A/ja active Pending
- 2012-09-12 JP JP2012200083A patent/JP2013005812A/ja active Pending
- 2012-10-15 US US13/651,808 patent/US8957041B2/en active Active
-
2013
- 2013-02-26 JP JP2013035574A patent/JP2013128488A/ja active Pending
-
2014
- 2014-02-11 US US14/177,640 patent/US9493771B2/en active Active
- 2014-12-18 IN IN10872DEN2014 patent/IN2014DN10872A/en unknown
- 2014-12-18 IN IN10874DEN2014 patent/IN2014DN10874A/en unknown
- 2014-12-18 IN IN10849DEN2014 patent/IN2014DN10849A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009535045A5 (enExample) | ||
| AU2013296321B2 (en) | Modified RNAi agents | |
| JP5244087B2 (ja) | 低分子内部セグメント化干渉ｒｎａ | |
| KR101697482B1 (ko) | 진단 및 치료 목적을 위한 마이크로ｒｎａ 및 다운스트림 타겟 | |
| JP6865169B2 (ja) | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 | |
| US8404659B2 (en) | Pharmaceutical compositions for treatment of MicroRNA related diseases | |
| US9074205B2 (en) | Nicked or gapped nucleic acid molecules and uses thereof | |
| EP3018209B1 (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease | |
| US20160115483A1 (en) | Silencing of polo-like kinase expression using interfering rna | |
| CN118879696A (zh) | 用于抑制载脂蛋白C-III(APOC3)的表达的RNAi试剂和组合物 | |
| JP2010537640A (ja) | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 | |
| JP2014097072A5 (enExample) | ||
| JP2023545502A (ja) | リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法 | |
| US20140356459A1 (en) | Micrornas and uses thereof | |
| EP2604690A1 (en) | MicroRNAs and uses thereof | |
| US20100055783A1 (en) | Nucleic acid compounds for inhibiting ras gene expression and uses thereof | |
| WO2025002247A1 (zh) | 靶向人血管生成素样蛋白3的核酸及其用途 | |
| CN113508175A (zh) | 用于治疗癌症的组合物和方法 | |
| US20240425853A1 (en) | Modified small interfering rna molecules with reduced off-target effects | |
| KR101861738B1 (ko) | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 | |
| JP2022524218A (ja) | Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用 | |
| EP4667571A1 (en) | Artificial mirna construct | |
| WO2018014848A1 (zh) | 一种小rna抑制剂 | |
| CN118256500A (zh) | 一种靶向FASN基因的siRNA、载体复合物及其应用 | |
| KR101993894B1 (ko) | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |